Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple Sclerosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004519-43